{"id":5744,"date":"2024-08-08T06:34:26","date_gmt":"2024-08-08T11:34:26","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=5744"},"modified":"2025-06-27T11:15:09","modified_gmt":"2025-06-27T16:15:09","slug":"nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2024\/08\/08\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\/","title":{"rendered":"Nanoscope Therapeutics se presentar\u00e1 en la cuarta conferencia virtual anual de oftalmolog\u00eda de HC Wainwright"},"content":{"rendered":"
\n
\n
\n

<\/h1>\n<\/div>\n<\/div>\n<\/div>\n
\n
\n
\n
\n

DALLAS<\/span><\/span>, TX \u2014 8 de agosto de 2024<\/span><\/span>\u00a0 \u2014 Nanoscopio Therapeutics Inc.<\/a>, una empresa de biotecnolog\u00eda cl\u00ednica en fase avanzada que desarrolla terapias gen\u00e9ticas para enfermedades hereditarias de la retina y degeneraciones maculares relacionadas con la edad (DMAE), anunci\u00f3 hoy que\u00a0Sulagna Bhattacharya<\/span>, Director General y\u00a0Samarendra Mohanty<\/span>, presidente de Nanoscope Therapeutics, presentar\u00e1 y participar\u00e1 en una mesa redonda en el\u00a02024 HC Wainwright 4th<\/sup>\u00a0Conferencia Virtual Anual de Oftalmolog\u00eda<\/a>, teniendo lugar el\u00a015 de agosto de 2024<\/span>.<\/p>\n

Los detalles de la presentaci\u00f3n son los siguientes:<\/p>\n

Tipo de sesi\u00f3n:\u00a0<\/b>Presentaci\u00f3n
Fecha de la sesi\u00f3n:<\/b>\u00a0Jueves 15 de agosto<\/span>
Tiempo de sesi\u00f3n:<\/b>\u00a07:00 a.m. hora del Este<\/span>
Presentadores:<\/b>\u00a0Sulagna Bhattacharya<\/span>, Director General y\u00a0Samarendra Mohanty<\/span>, Doctorado, Presidente<\/p>\n

La Sra. Bhattacharya y el Dr. Mohanty ofrecer\u00e1n una actualizaci\u00f3n corporativa sobre las pr\u00f3ximas actividades de Nanoscope tras los resultados positivos de la fase final del ensayo cl\u00ednico aleatorizado de MCO-010 en pacientes con retinosis pigmentaria (RP) y del ensayo de fase 2 en la enfermedad de Stargardt. La presentaci\u00f3n tambi\u00e9n introducir\u00e1 la plataforma de administraci\u00f3n l\u00e1ser de pr\u00f3xima generaci\u00f3n MCO-020 para la terapia g\u00e9nica no viral de las atrofias geogr\u00e1ficas (AG) secundarias a la DMAE. A continuaci\u00f3n, tendr\u00e1 lugar una mesa redonda sobre programas cl\u00ednicos avanzados dirigidos a indicaciones retinianas, moderada por Yi Chen, PhD, Director Gerente de Investigaci\u00f3n de Renta Variable en HC Wainright. Los detalles de la mesa redonda son los siguientes:<\/p>\n

T\u00edtulo de la sesi\u00f3n:<\/b>\u00a0Candidatos en etapa tard\u00eda sin riesgo para trastornos de la retina
Tipo de sesi\u00f3n:<\/b>\u00a0Panel de discusi\u00f3n
Fecha de la sesi\u00f3n:\u00a0<\/b>Jueves 15 de agosto\u00a0
Tiempo de sesi\u00f3n:\u00a0<\/b>11:00 a. m. hora del Este<\/span>,
Miembro del jurado:\u00a0<\/b>Samarendra Mohanty<\/span>, Doctorado, Presidente<\/p>\n

Los panelistas discutir\u00e1n los caminos que han forjado para sus respectivos programas hacia un estado cl\u00ednico avanzado. Esto incluir\u00e1 informaci\u00f3n sobre la navegaci\u00f3n de la econom\u00eda de fabricaci\u00f3n, regulatoria y de salud en el camino hacia la aprobaci\u00f3n y el lanzamiento comercial.<\/p>\n

Para registrarse para la transmisi\u00f3n web en vivo, comun\u00edquese con su representante de HC Wainwright. Una repetici\u00f3n del webcast estar\u00e1 disponible a trav\u00e9s de HC Wainwright por un tiempo limitado despu\u00e9s del evento.<\/p>\n

Acerca de Nanoscope Therapeutics Inc.
<\/b>Nanoscope Therapeutics est\u00e1 desarrollando terapias optogen\u00e9ticas gen\u00e9ticamente independientes que restauran la vista para los millones de pacientes cegados por enfermedades hereditarias de la retina, para las cuales no existe cura. El principal activo de la empresa, MCO-010,\u00a0anunci\u00f3 recientemente los datos de 100 semanas de<\/a>\u00a0la fase de RESTAURACI\u00d3N\u00a02b<\/span>\/3 ensayo cl\u00ednico multic\u00e9ntrico, aleatorizado, doble enmascarado y controlado de forma simulada en los EE. UU. para la retinosis pigmentaria (NCT04945772<\/a>). La compa\u00f1\u00eda tambi\u00e9n complet\u00f3 recientemente el ensayo de fase 2 STARLIGHT de la terapia MCO-010 en pacientes con enfermedad de Stargardt (NCT05417126<\/a>). MCO-010 ha recibido designaciones de v\u00eda r\u00e1pida de la FDA y designaciones de medicamento hu\u00e9rfano de la FDA tanto para la retinitis pigmentosa como para la enfermedad de Stargardt. Los activos precl\u00ednicos incluyen la terapia g\u00e9nica MCO-020 administrada con l\u00e1ser no viral para la GA secundaria a AMD.<\/p>\n

Contacto de inversores:<\/b>
Socios Argot
212-600-1902
PR@nanostherapeutics.com<\/a><\/p>\n<\/div>\n<\/div>\n<\/section>\n<\/article>","protected":false},"excerpt":{"rendered":"

DALLAS, TX \u2014 Aug. 8, 2024\u00a0 \u2014 Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), today announced that\u00a0Sulagna Bhattacharya, Chief Executive Officer and\u00a0Samarendra Mohanty, President of Nanoscope Therapeutics, will present and participate in a panel discussion at the\u00a02024 H.C. Wainwright 4th\u00a0Annual Ophthalmology Virtual […]<\/p>\n","protected":false},"author":6,"featured_media":5746,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-5744","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"\nNanoscope Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2024\/08\/08\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2024\/08\/08\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2024-08-08T11:34:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-27T16:15:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_LI_BIO_Intl_2024_V2.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_ARVO_LI_2024._V2.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/08\\\/08\\\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/08\\\/08\\\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference\",\"datePublished\":\"2024-08-08T11:34:26+00:00\",\"dateModified\":\"2025-06-27T16:15:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/08\\\/08\\\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\\\/\"},\"wordCount\":418,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/08\\\/08\\\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/08\\\/NSCOPE_LI_Wainwright2024rev2.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/08\\\/08\\\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/08\\\/08\\\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\\\/\",\"name\":\"Nanoscope Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/08\\\/08\\\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/08\\\/08\\\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/08\\\/NSCOPE_LI_Wainwright2024rev2.jpg\",\"datePublished\":\"2024-08-08T11:34:26+00:00\",\"dateModified\":\"2025-06-27T16:15:09+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/08\\\/08\\\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/08\\\/08\\\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/08\\\/08\\\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/08\\\/NSCOPE_LI_Wainwright2024rev2.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/08\\\/NSCOPE_LI_Wainwright2024rev2.jpg\",\"width\":1200,\"height\":1200},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/08\\\/08\\\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics presentar\u00e1 sus novedades en la 4.\u00aa Conferencia Virtual Anual de Oftalmolog\u00eda de HC Wainwright.","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2024\/08\/08\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2024\/08\/08\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2024-08-08T11:34:26+00:00","article_modified_time":"2025-06-27T16:15:09+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_LI_BIO_Intl_2024_V2.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_image":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_ARVO_LI_2024._V2.jpg","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Nanoscope Therapeutics","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2024\/08\/08\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2024\/08\/08\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference","datePublished":"2024-08-08T11:34:26+00:00","dateModified":"2025-06-27T16:15:09+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/08\/08\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\/"},"wordCount":418,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/08\/08\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/08\/NSCOPE_LI_Wainwright2024rev2.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2024\/08\/08\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\/","url":"https:\/\/nanostherapeutics.com\/2024\/08\/08\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\/","name":"Nanoscope Therapeutics presentar\u00e1 sus novedades en la 4.\u00aa Conferencia Virtual Anual de Oftalmolog\u00eda de HC Wainwright.","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/08\/08\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/08\/08\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/08\/NSCOPE_LI_Wainwright2024rev2.jpg","datePublished":"2024-08-08T11:34:26+00:00","dateModified":"2025-06-27T16:15:09+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2024\/08\/08\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2024\/08\/08\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2024\/08\/08\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/08\/NSCOPE_LI_Wainwright2024rev2.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/08\/NSCOPE_LI_Wainwright2024rev2.jpg","width":1200,"height":1200},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2024\/08\/08\/nanoscope-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"Terap\u00e9utica del nanoscopio"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5744","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=5744"}],"version-history":[{"count":2,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5744\/revisions"}],"predecessor-version":[{"id":9040,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5744\/revisions\/9040"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/5746"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=5744"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=5744"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=5744"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}